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OBJECTIVES We tested the hypothesis that cardioprotection with ischemic preconditioning (PC) is lost in
the aging, or senescent, heart.
BACKGROUND Although infarct size reduction with PC has been documented in virtually all models, a
purported exception to this paradigm is the aging heart, the population in which cardiopro-
tection is most relevant. However, no previous studies have assessed the concept of an
age-associated loss in the efficacy of PC in an in vivo model of acute myocardial infarction in
which definitive hallmarks of cardiovascular aging were demonstrated and a reduction of
infarct size, the “gold standard” of PC, served as the primary end point.
METHODS Using the in vivo rabbit model, three cohorts of animals were studied: adult (4 to 6 months
old), middle-aged (2 years old) and old (4 years old) rabbits. Within each cohort we
assessed: 1) infarct size (measured by tetrazolium staining and expressed as percent
myocardium at risk) in control and PC groups; and 2) morphologic and functional hallmarks
of cardiovascular aging (progressive myocyte hypertrophy, increased myocardial fibrosis and
attenuated responsiveness to beta-adrenergic stimulation).
RESULTS In adult animals, infarct size was significantly smaller in the PC group than in the control
group (29  4% vs. 57  2%; p  0.01). Although middle-aged and old rabbits exhibited all
three archetypal indexes of cardiovascular aging, a comparable (50%) reduction in infarct
size with PC was evident in both cohorts.
CONCLUSIONS These data provide the first in vivo evidence that infarct size reduction with PC is not
precluded by increased cardiovascular age, per se. (J Am Coll Cardiol 2001;38:1741–7)
© 2001 by the American College of Cardiology
It has been well established that brief episodes of ischemia
can protect, or ‘precondition’, the heart and significantly
limit infarct size caused by a subsequent, sustained period of
coronary artery occlusion (1). Indeed, cardioprotection with
preconditioning (PC) has been documented in virtually all
experimental models and, importantly, may also be evident
in the clinical setting (1,2). However, one purported excep-
tion to this paradigm is the aging heart: evidence obtained
from the rat model suggests that the benefits of PC wane
with increasing age and are lost in the hearts of senescent
animals (3–10).
As the aging cohort is undoubtedly the population in
which acute myocardial infarction (MI) is most prevalent
and cardioprotection is most relevant (11,12), a loss in
efficacy of ischemic PC with increasing age would have
profound, but hitherto largely unexplored clinical implica-
tions (13–16). However, this concept is based exclusively on
studies conducted in isolated buffer-perfused heart prepara-
tions that relied primarily on a surrogate index of cardio-
protection—namely, the early recovery of left ventricular
(LV) function after relief of sustained global ischemia
(3–10). No previous studies have addressed the issue of an
age-related loss in the efficacy of PC in an in vivo,
blood-perfused model of acute MI in which: 1) definitive
hallmarks of cardiovascular aging were demonstrated; and 2)
a reduction of infarct size, the recognized “gold standard” of
PC (1), served as the primary end point.
Using the in vivo rabbit model, we quantified infarct size
reduction with PC in adult (4 to 6 months old), middle-
aged (24 to 27 months old) and old (42 to 60 months old)
animals. We report that, despite conclusive morphologic
and functional evidence of cardiovascular aging in the
middle-aged and old populations (e.g., myocyte hypertro-
phy, increased myocardial fibrosis and attenuated response
to beta-adrenergic stimulation [17–23]), the efficacy of
infarct size reduction with PC is preserved in both middle-
aged and old rabbits. Thus, our results provide the first
evidence that cardioprotection by ischemic PC is not pre-
cluded by increased cardiovascular age, per se, in an in vivo
model of acute MI.
METHODS
This study was approved by the Institutional Animal Care
and Use Committee of Good Samaritan Hospital and
conforms to the “Position of the American Heart Associa-
tion on Research Animal Use,” adopted in November 1984.
Protocol 1: Infarct Size and
Morphologic Confirmation of Aging
Surgical preparation. Thirty-eight pathogen-free New
Zealand White rabbits were anesthetized with intramuscu-
lar injections of ketamine (200 mg) plus xylazine (100 mg),
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given twice before the start of the operation. The rabbits
were intubated and ventilated with room air supplemented
with 100% oxygen. After cannulating the left jugular vein
(for administration of fluids) and the left carotid artery (for
measurement of heart rate and arterial pressure), the heart
was exposed through a left thoracotomy, and a large
marginal branch of the circumflex artery was encircled with
a snare for later occlusion/reperfusion. Continuous tracings
of arterial pressure were obtained on a chart recorder, and
body temperature (monitored using a rectal thermometer)
was maintained at 38°C to 39°C. Surgical anesthesia was
maintained by intraperitoneal injections of sodium pento-
barbital (50 mg/h) throughout the protocol.
Study design. Three cohorts of rabbits were studied: adult
(4 to 6 months old; mean body weight 3.0  0.1 kg; n 
14), middle-aged (24 to 27 months old; weight 4.1 
0.2 kg; n 12) and the oldest commercially available rabbits
(42 to 60 months old; weight 4.6  0.1 kg; n  12). Within
each cohort, rabbits were randomized to receive either 5 min
of PC ischemia plus 10 min of reflow or a matched 15-min
control period (n  6 to 8 per group). All animals then
underwent 30 min of sustained coronary artery occlusion
followed by 3 h of reperfusion.
At the end of each experiment, the extents of the area at
risk of infarction (AR) and area of necrosis (AN) were
determined using routine methods (24). Briefly, the coro-
nary artery was reoccluded, and the AR was delineated by
injection of blue pigment through a left atrial catheter. After
euthanizing the rabbits under deep anesthesia (300 mg of
intravenous xylazine, followed by 10 mEq of potassium
chloride into the left atrium), the hearts were rapidly
excised, cut into five or six transverse slices and photo-
graphed. The slices were then incubated in 1% triphenyl-
tetrazolium chloride (10 min a 37°C) to distinguish necrotic
from viable myocardium, rephotographed and stored in 10%
neutral buffered formalin.
Analysis. HEMODYNAMIC DATA. The heart rate, mean ar-
terial pressure and rate-pressure product (heart rate  mean
arterial pressure) were measured at baseline (before random-
ization), after the control or PC period (immediately before
sustained occlusion), at 25 min of occlusion and at 15 min
and 3 h after reperfusion.
RISK REGION AND INFARCT SIZE. Right ventricular tissue
was trimmed from each heart slice, and the remaining LV
was weighed. Photographic images of the tissue slices were
projected and traced at magnifications of 5 to 10. The
AR and AN in each slice were quantified by computerized
planimetry, corrected for tissue weight and summed for each
heart. The AR was then expressed as percent total LV
weight, and AN was expressed as percent of the AR (24).
MYOCYTE HYPERTROPHY AND MYOCARDIAL FIBROSIS.
One LV slice, located midway between the apex and the
base, was taken from each heart and processed for paraffin
embedding. For assessment of myocyte hypertrophy, cross
sections (5 m thick) were stained with hematoxylin and
eosin, viewed in brightfield using a 40 objective lens and
displayed on a high-resolution monitor. Myocyte cross-
sectional areas in noninfarcted myocardium (25 per heart)
were quantified by computerized planimetry (25). Myocar-
dial fibrosis was determined from additional 5-m cross
sections stained with picrosirius red (which stains muscle
yellow and collagen red) by a video subtraction method
developed in our laboratory (26). Briefly, both a blue-
filtered brightfield image and a circularly polarized image
were obtained from three noninfarcted regions per heart
(20 objective lens; 0.06 mm2 per region). Using video
analysis software, the monochrome brightfield image (in
which collagen appears dark and muscle is bright) was
subtracted from the circularly polarized image (in which
both muscle and collagen appear bright), resulting in a
subtracted image composed of bright collagen on a black
(i.e., gray scale level of 0) background. A histogram of the
brightness of each pixel in the image was generated, and the
percent collagen content was calculated (26) as:
pixels with a gray scale level 0 /
total number of pixels 100%	
Protocol 2: Functional Confirmation of Aging
Surgical preparation, study design and analysis. Eight
additional rabbits (3 adult, 2 middle-aged and 3 old) were
anesthetized and ventilated as described in Protocol 1. In
this case, however, a fluid-filled catheter was advanced into
the LV cavity through the left carotid artery for measure-
ment (closed chest) of LV pressure and its first derivative,
LV dP/dt. After obtaining a baseline measurement of LV
contractility, each rabbit received sequential 5-min intrave-
nous infusions of the beta-adrenergic agonist isoproterenol
at concentrations of 0.1, 0.2, 0.5 and 1.0 g/kg body weight
per min (27). At the end of each 5-min infusion, at which
time hemodynamic variables had stabilized, heart rate and
peak positive LV dP/dt (dP/dtmax) were assessed and
expressed as a percentage of the baseline values for each
rabbit.
Statistics. For Protocol 1, all discrete variables (AR/LV,
AN/AR, myocyte cross-sectional area and fibrosis) were
compared by two-factor analysis of variance (ANOVA), for
Abbreviations and Acronyms
AN  area of necrosis
ANCOVA  analysis of covariance
ANOVA  analysis of variance
AR  area at risk of infarction
dP/dtmax  peak positive LV dP/dt
LV  left ventricular
LV dP/dt  first derivative of LV pressure
MI  myocardial infarction
NE  norepinephrine
PC  preconditioning
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age and treatment. Within each age group, infarct size was
further compared between control and PC animals by
analysis of covariance (ANCOVA), incorporating the risk
region—the major determinant of infarct size in the rab-
bit—as the covariate. Hemodynamic variables were com-
pared using three-factor ANOVA, for age, treatment and
time, with repeated measures. For Protocol 2, the percent
change in heart rate and dP/dtmax were compared using
two-factor ANOVA, for age and dose of isoproterenol, with
repeated measures. Post-hoc pairwise comparisons were
made using the Newman-Keuls test. All data are expressed
as the mean value  SEM.
RESULTS
Protocol 1
Hemodynamic data. There were no differences in the
heart rate, mean arterial pressure or rate-pressure product
between the control and PC rabbits in any age group (Table 1).
Adults exhibited the characteristic temporal hemody-
namic changes described for anesthetized rabbits: i.e., heart
rate increased, whereas the mean arterial pressure and
rate-pressure product decreased during the course of the
protocol (24). For all time points, middle-aged and old
rabbits displayed the expected trend toward lower values of
heart rate and mean arterial pressure (19), as well as a
significant reduction in the rate-pressure product, as com-
pared with the adult cohort (Table 1).
Risk region and infarct size. The AR averaged 33% to
37% of the total LV weight in the six study groups (p  NS
for control vs. PC groups; p  NS for age) (Fig. 1A).
In the adult cohort, the mean infarct size was, as
expected, significantly reduced in PC rabbits versus control
rabbits, with AN/AR averaging 29  4% versus 57  2%,
respectively (p  0.01) (Fig. 1B). Similar profound cardio-
protection was also observed with PC in both the middle-
aged and old populations: AN/AR was 20  4% versus
48  3% in middle-aged PC versus control rabbits (p 
0.01) and 25  5% versus 50  4% in old PC versus control
animals (Fig. 1B). This was confirmed by ANCOVA,
incorporating the mass of the risk region as a covariate in
Table 1. Hemodynamic Data
Baseline
Occlusion Reperfusion
Preocclusion 25 min 15 min 3 h
Heart rate (beats/min)
Adult rabbits
Control 166  4 165  5 167  7 172  7 192  9†
PC 160  9 157  9 170  7 173  8 203  10†
Middle-aged rabbits
Control 145  10 144  9 153  9 154  9 157  7*
PC 136  6 133  5 139  7* 136  5* 141  9*
Old rabbits
Control 146  12 154  12 161  7 162  4 168  8†
PC 152  7 154  7 158  9 151  8 155  8*
Mean arterial pressure (mm Hg)
Adult rabbits
Control 90  3 86  3 74  3† 70  1† 54  4†
PC 86  3 81  3 71  2† 67  2† 48  3†
Middle-aged rabbits
Control 81  7 77  7 61  7† 53  8† 48  3†
PC 84  5 73  6 64  4† 60  6† 49  3†
Old rabbits
Control 84  5 77  7 66  7† 60  8† 46  4†
PC 81  3 72  2 65  2† 62  3† 49  3†
Heart rate  mean arterial
pressure (beats/min 
mm Hg  103)
Adult rabbits
Control 15.0  0.5 14.1  0.5 12.2  0.5† 12.0  0.4† 10.2  0.8†
PC 13.6  0.5 12.5  0.5 12.3  0.5† 11.6  0.4† 9.7  0.4†
Middle-aged rabbits
Control 11.4  0.6* 10.7  0.5* 9.1  0.5*† 7.8  0.8*† 7.4  0.3*†
PC 11.3  0.7* 9.7  0.8* 8.9  0.7*† 8.0  0.8*† 6.8  0.3*†
Old rabbits
Control 12.5  1.6* 11.9  1.6* 10.6  1.0 9.6  1.2* 7.6  5*†
PC 12.2  0.4* 10.9  0.2* 10.2  0.6*† 9.3  0.2*† 7.5  0.5*†
For all variables: treatment (control vs. PC): p  NS; time: †p  0.05 versus corresponding baseline value; age: *p  0.05 versus
corresponding adult group.
PC  preconditioned.
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the analysis; for all age groups, infarct mass was significantly
reduced in PC rabbits versus age-matched control rabbits
(p  0.01 for all ages; data not shown).
Myocyte hypertrophy and myocardial fibrosis. As ex-
pected, there were no differences in myocyte size or percent
collagen content between control versus PC rabbits in any of
the three age groups (Fig. 2A and 2B).
Mean myocyte cross-sectional area for the total adult
population was 397  7 m2. Both the middle-aged and
old cohorts exhibited significant progressive hypertrophy;
the myocyte cross-sectional areas for the pooled control and
PC groups were 445  11 m2 in middle-aged rabbits (p 
0.01 vs. adults) and 511  8 m2 in old animals (p  0.01
vs. adults and p  0.01 vs. middle-aged rabbits) (Fig. 2A).
Myocardial collagen content in the adult rabbits (pooled
control and PC groups) averaged 6.2  0.3%. There was an
increase in the percent collagen content with age (Figs. 2B and
3), to a mean value of 7.6 0.3% in middle-aged rabbits (p
0.05 vs. adults) and 10.8  0.5% in old rabbits (p  0.01 vs.
adults and p  0.01 vs. middle-aged rabbits) (Fig. 2B).
Protocol 2
Adult rabbits showed a robust and dose-dependent increase
in both heart rate and contractility with isoproterenol; at the
highest dose of 1.0 g/kg/min, heart rate and LV dP/dtmax
increased to 188  5% and 247  14% of baseline,
respectively (p  0.01 vs. baseline). The increase in heart
rate in response to isoproterenol was similar, for all doses, in
both the middle-aged and old cohorts, as compared with the
adult cohort (p  0.55 for age; data not shown). In contrast,
the isoproterenol-induced increase in dP/dtmax was blunted
in middle-aged rabbits and abrogated in old rabbits (153 
11% and 96  12% of baseline, respectively, with 1.0 g/kg
per min; p  0.01 vs. adults) (Fig. 4).
DISCUSSION
We report that, in rabbits exhibiting definitive hallmarks of
cardiovascular aging (i.e., myocyte hypertrophy, myocardial
fibrosis and attenuated contractile responsiveness to beta-
adrenergic stimulation), ischemic PC significantly limited
infarct size, with no loss of efficacy in middle-aged or old
rabbits versus adult rabbits. These data provide the first in
vivo evidence that cardiovascular aging does not render PC
ineffective in protecting the heart against infarction.
Cardiovascular consequences of aging. Aging, per se,
even in the absence of concurrent disease, has profound
cardiovascular consequences that are consistently observed
Figure 1. (A) Risk region, expressed as percent total left ventricular (LV)
weight, for adult, middle-aged and old rabbits. Results of two-way analysis
of variance: p  0.79 for age; p  0.94 for treatment; and p  0.40 for
age  treatment. (B) Necrosis, expressed as percent risk region, for adult,
middle-aged and old rabbits. Results of two-way analysis of variance: p 
0.05 for age; p  0.01 for treatment; and p  0.90 for age  treatment.
**p  0.01 versus matched control group. Solid bars  control groups;
open bars  PC groups.
Figure 2. (A) Myocyte cross-sectional area (m2) in adult, middle-aged
and old rabbit hearts. Results of two-way analysis of variance: p  0.01 for
age; p  0.75 for treatment; and p  0.98 for age  treatment. (B) Percent
collagen content in adult, middle-aged and old rabbit hearts. Results of
two-way analysis of variance: p  0.01 for age; p  0.41 for treatment; and
p  0.97 for age  treatment. *p  0.05 and †p  0.01 versus adult
rabbits; ‡p  0.01 versus middle-aged rabbits. Solid bars  control
groups; open bars  PC groups.
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in experimental models and in humans. Among these,
perhaps the best-documented are progressive myocyte hy-
pertrophy, accompanying myocardial fibrosis and marked
alterations in G protein-mediated cellular signaling path-
ways, including a long-appreciated reduction in responsive-
ness to beta-adrenergic stimulation (17–23).
The rabbit has not, historically, been extensively em-
ployed in aging studies. Indeed, there has been some dispute
as to the maximal life span of the rabbit, with values of both
7 years (28) and 13 years (29) having been reported. For this
reason, we considered it imperative to document indexes of
cardiovascular aging in our model and, further, to compare
our findings with published data on 2-year-old rats, an
accepted model of “senescence” (17). We observed a 1.3-
fold increase in myocyte cross-sectional area and a 1.7-fold
increase in percent collagen content in 4-year-old rabbits,
as compared with the adult cohort. Despite fundamental
differences in tissue fixation, histologic processing and
methods of analysis among studies, these data compare
favorably with the 1.2- to 2.2-fold increases in myocyte size
(area or volume) (18,19) and the 1.2- to 3.3-fold increases in
percent collagen content (18) described in 23- to 29-
month-old rats. Moreover, our results are consistent with
autopsy data from patients who died of causes other than
cardiovascular disease, showing a 1.3-fold increase in
myocyte volume between 20 and 75 years of age (20).
With regard to the functional index of cardiovascular
aging— beta-adrenergic responsiveness— comparisons
among studies are again complicated by methodologic
differences, including the use of in vitro rather than in vivo
preparations, administration of bolus doses rather than
infusions of isoproterenol and, in clinical studies, measure-
ment of noninvasive indexes of LV function rather than the
direct assessment of dP/dt. Most previous studies have
reported that the isoproterenol-induced increases in both
heart rate and LV contractility are blunted, but not abro-
gated, with increasing age (21–23,30). In contrast, we found
that the effect of isoproterenol on dP/dt was completely
abolished in 4-year-old rabbits, with no accompanying
change in the heart rate response. Although we cannot
provide a definitive explanation for the difference between
our results and the concomitant but subtotal attenuation of
heart rate and contractility seen in other models, this may
reflect purported differences among species in adrenergic
receptor density, signaling and control (27,30) or the pos-
Figure 3. Picrosirius red-stained sections from adult (A), middle-aged (B)
and old (C) rabbit hearts, viewed with circularly polarized light, illustrating
the age-related increase in myocardial collagen content. Thick collagen
fibers appear yellow; thin fibers appear yellow-green; and myocytes are
green and cross striated. Bar  50 m.
Figure 4. Peak positive LV dP/dt (LV dP/dtmax; expressed as a percentage
of baseline values) during isoproterenol infusion in adult, middle-aged and
old rabbits. Results of two-way analysis of variance: p  0.01 for age; p 
0.01 for dose; and p  0.01 for age  dose. †p  0.01 versus adults; §p 
0.01 versus baseline. Solid bars  adult rabbits; striped bars  middle-
aged rabbits; open bars  old rabbits.
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sible effects of the ketamine plus xylazine anesthesia em-
ployed in our protocol. Nonetheless, the significant myocyte
hypertrophy and fibrosis observed with increasing age,
together with the complete inability of isoproterenol to elicit
an increase in contractility in the 4-year-old rabbits,
provide compelling evidence for cardiovascular aging in our
rabbit model.
Age and the efficacy of PC. There is no question that the
clinical incidence of coronary artery disease and acute MI is
increased with age. In one recent trial, the median age of
patients with acute MI was 62 years to 64 years, with only
4% of patients being 40 years of age (12). Thus, the
aging cohort is precisely the population in which cardiopro-
tection with ischemic PC is most relevant. However, only
four clinical studies have focused on whether brief anteced-
ent ischemia (i.e., preinfarct angina) continues to confer
protection in the elderly patient with MI. Two studies have
concluded that, in patients 
60 years old (13) or 
64 years
old (14), the in-hospital outcome was improved and creatine
kinase release was attenuated in cohorts with versus without
preinfarct angina, whereas the other two studies found that
preinfarct angina had no favorable effect on creatine kinase
release, in-hospital outcome and five-year mortality in
subsets of patients 65 and 70 years old (15,16). The
reasons for this disparity are unknown, but, as with any
clinical protocol seeking to assess the efficacy of ischemic
PC, the requisite reliance on indirect enzymatic indexes of
myocardial necrosis, as well as possible confounding differ-
ences in baseline characteristics (e.g., risk factors, incidence
of multivessel disease, history of previous MI, use of
anti-anginal drugs) among studies may all play a role.
Seemingly discrepant results have also been obtained in
experimental models. Although there are two reports of
persistent cardioprotection, irrespective of age, with PC
(31,32), questions have been raised regarding the interpre-
tation of these data. Specifically, the studies found that PC
limited infarct size in 5.7- to 8-year-old sheep (31) and in
isolated hearts harvested from rabbits 135 weeks old (32).
However, the lengthy life span of both of these species,
together with the lack of functional or morphologic evi-
dence of cardiovascular aging in these protocols, makes it
unclear as to whether these can truly be considered “old”
populations. In contrast, all other experimental studies—all
of which have employed the isolated buffer-perfused rat
heart—have concluded that the benefits of PC wane in 9-
to 12-month-old rats (3–5,8,10) and are lost in 11⁄2- to
2-year-old animals (4,6,7,9,10). Interestingly, although car-
diovascular indexes of aging were not concomitantly as-
sessed in these later protocols, the progressive loss in efficacy
of PC in 9- to 12-month-old rats appears, on the basis of
morphologic studies, to precede the age-associated develop-
ment of myocyte hypertrophy and increased fibrosis in this
species (18,19).
Reconciling the data. Our study represents the first evi-
dence that, in an in vivo model of acute MI exhibiting
definitive hallmarks of cardiovascular aging, infarct size
reduction with PC continues to be evident in middle-aged
and old cohorts. How can we reconcile our data with the
results obtained in the rat model, all reporting a loss in the
efficacy of PC with age?
Two potential explanations warrant consideration. First,
the discrepancy may reflect differences in the preparations
and end points used. Specifically, all previous studies em-
ploying rats used isolated, paced and buffer-perfused hearts,
and, perhaps more importantly, only two of these protocols
measured infarct size (9,10), whereas all of the other studies
relied exclusively on recovery of LV function as the primary
end point. Although an early improvement in contractility
after relief of sustained ischemia (i.e., attenuation of post-
ischemic “stunning”) is typically cited as evidence of protec-
tion in studies employing the isolated buffer-perfused heart,
it is well recognized that, in contrast to the “gold standard”
of infarct size reduction, this does not represent a consistent
or reliable index of cardioprotection with ischemic PC
(1,33). Moreover, there is evidence that postischemic stun-
ning may be exacerbated in the senescent rat heart (34),
thereby raising further questions as to the suitability of this
variable as a surrogate end point for PC-induced protection
in aging populations. Second, the conflicting results may be
due to underlying mechanistic differences between species.
For example, there is evidence that, in the rat heart,
norepinephrine (NE) is released in response to brief isch-
emia and may, through stimulation of alpha1-adrenergic
receptors, participate in the reduction in infarct size
achieved with PC (1,35). Moreover, the loss in efficacy of
PC in aging rat hearts has been attributed to an age-
associated reduction in cardiac NE release (7). In contrast,
NE release after brief ischemia is negligible in rabbit, as well
as human, hearts (36,37), and, although exogenous NE can
limit infarct size in the myocardium of rabbits, endogenous
NE does not appear to be mandatory for PC-induced
cardioprotection in this species (1,36). Further prospective
studies will be required to establish whether differences in
the role of NE (or other as yet unidentified mediators) may
be responsible for the different outcomes in the rat versus
rabbit model.
Conclusions and future directions. Our results reveal a
significant and persistent reduction of infarct size with
ischemic PC—irrespective of increasing age—in the in vivo
rabbit model of acute MI. Although the cellular mecha-
nisms of PC-induced cardioprotection may differ in adult
versus senescent populations—a hitherto unexplored issue
that awaits further study—we nonetheless provide the first
in vivo evidence that infarct size reduction with PC is not
precluded by increased cardiovascular age, per se.
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